LLY
Wall Street’s latest Lilly crush
Berenberg just raised Eli Lilly to Buy and set a $1,400 price target, basically saying the pharma giant still has room to run even after a monster move. When analysts start tossing around four-digit targets, it usually means they think the market’s still underappreciating the company’s growth engine.
Why you should care
Lilly has become one of those stocks that can make a whole sector look lazy. The company’s obesity and diabetes drugs have turned into a full-blown growth machine, and upgrades like this can help keep the bullish narrative alive.
A few investor takeaways:
- The new target suggests Berenberg sees more upside from Lilly’s pipeline and commercial momentum.
- It also reinforces that analysts still view Lilly as a category leader in the GLP-1 race.
- For holders, it’s a reminder that the Street isn’t ready to call peak Lilly just yet.
Big picture
This isn’t the kind of news that rewrites the business overnight, but it does keep the valuation conversation spicy. If you own LLY, you’re basically watching Wall Street try to guess how long the company’s obesity-fueled growth streak can last before gravity shows up.